Navigation Links
Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Luke's Cancer Center
Date:6/3/2008

NEW YORK, June 3 /PRNewswire-FirstCall/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that the St. Luke's Cancer Center of Bethlehem, PA, part of St. Luke's Hospital & Health Network (St. Luke's), has joined Delcath's Phase III clinical trial for the treatment of inoperable metastatic melanoma in the liver using the Company's Percutaneous Hepatic Perfusion (PHP) System for the isolated, high dose delivery of the anti-cancer agent melphalan. This Phase III multi-center study is led by the National Cancer Institute (NCI) and is enrolling at cancer centers throughout the United States.

Delcath has finalized a clinical research agreement with St. Luke's. Sanjiv Agarwala, M.D., Chief of Oncology and Hematology, will serve as the Principal Investigator of the study at St. Luke's. Dr. Agarwala, a leader in the field of melanoma and clinical oncology, commented, "Metastatic melanoma in the liver presents a devastating cancer with no effective treatment options. We are very pleased to be able to provide this option to patients suffering from this disease. This is a study with tremendous potential to treat patients with aggressive disease burden and is a promising advance in the field of liver directed regional therapy."

"The addition of St. Luke's and Dr. Agarwala to this trial, which follows the recent announcement that the University of Maryland will commence enrollment of patients, is expected to be followed by the announcement of additional centers during the summer. Delcath continues to expand this Phase III study to leading cancer centers and we welcome this collaboration with St. Luke's, as it further allows the Delcath PHP System to reach patients who can benefit from this treatment option," said Richard L. Taney, P
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
2. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
3. BiPar Sciences Expands Clinical Development of BSI-201, A Novel PARP Inhibitor, With Phase 2 Trial in Uterine Cancer
4. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
5. CoreSpine Technologies Expands Spinal Disc Site Preparation Efforts
6. Alseres Pharmaceuticals Expands Sites for the First Stage of the ALTROPANE(R) Phase III Clinical Trial Program
7. Senesco Expands on Recently Announced Preclinical Pancreatic Islet Data
8. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
9. PAREXEL Expands Global Clinical Pharmacology Capabilities
10. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
11. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)BETHESDA, Md., Dec. 4 Drs. Neal Shore and E. David Crawford presented results for prostate-specific antigen (PSA) recurrence from the additional analysis of secondary end points of biochemical recurr
(Date:12/4/2009)RARITAN, N.J., Dec. 4 Depression, anxiety disorder, bipolar disorder, Attention Deficit Hyperactivity Disorder (ADHD), sleep disorder and migraine: These are among the comorbidities reported to occur
(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,
Breaking Medicine Technology:Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 2Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 3Degarelix (FIRMAGON(R)) vs Leuprolide (Lupron Depot(R)) in Patients With Advanced Prostate Cancer: Further Analysis From a Phase III Pivotal Trial 4Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 1Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 2Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 3Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 4Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 5Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 6Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 7Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 8Survey Shows At Risk Men Lacking In Prostate Cancer Knowledge 56594 9PDL BioPharma to Present at BioCentury Newsmakers Conference on September 16 2009 56592 1Major clinical study rejects cancer safety fears of most common heartburn treatment 56590 1Major clinical study rejects cancer safety fears of most common heartburn treatment 56590 2
...ith the continued aging of,the population and the ...f,the disease is crucial for risk assessment, test... with better drugs, once they are developed.,Four ...ion,s 2008,International Conference on Alzheimer,s... that goal of early detection by describing advanc...
...29 Bladder problems may,leave a mark on the brain...,contributing to disrupted sleep and problems with...active bladder, the involuntary bladder contractio...te, such mind-body,connections may be of more than...ust one organ, but here we see how an,abnormal org...
Other Medicine Technology:Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimer's 2Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimer's 3Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimer's 4Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimer's 5Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimer's 6Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimer's 7Markers in Blood and Spinal Fluid, and a New Imaging Agent, Show Promise for Early Detection of Alzheimer's 8Findings on Bladder-Brain Link May Point to Better Treatments for Problems in Sleep, Attention 2
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
(Date:12/4/2009)Case Western Reserve University researchers, from the School of Medicine,s Department of Nutrition, discovered two new metabolic pathways by which products of lipid peroxidation and some drugs of abus
(Date:12/4/2009)Rockville, MD "Why is it that men can be bastards and women must wear pearls and smile?" wrote author Lynn Hecht Schafran. The answer, according to an article in the Journal of Vision , may lie in
(Date:12/4/2009)Outcomes same whether procedure done immediately or 3 weeks later, study shows , , FRIDAY, Dec. 4 (HealthDay News) -- Timing of surgical repair or reconstruction of multiple-ligament knee inju
(Date:12/4/2009)Move a response to pressure from federal regulators to crack down on abuse of opioid medications , , FRIDAY, Dec. 4 (HealthDay News) -- The makers of 24 different prescription painkillers on F
Breaking Medicine News(10 mins):Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4Health News:Case Western Reserve researchers' new pathway discovery published as 'Paper of the Week' 2Health News:Are angry women more like men? 2Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:Makers of Powerful Painkillers Present Safety Plans 2
...APEL HILL, N.C., Oct. 3 With declining revenues a...s look to other functions,such as Medical Affairs,...,as a productive cost center. To achieve this goal...suring the creation of,winning products. Best Pra...
...ODCLIFF LAKE, N.J., Oct. 2 Duramed,Pharmaceutical.... (NYSE:,BRL), announced today the launch of its m...t of moderate-to-severe vaginal dryness and pain w... the treatment of these specific symptoms associat...
...st Day to Register October 11, 2007, DENVER, Oct.... in the water industry will build on their knowled...sted by the American Water,Works Association (AWWA... used for the,treatment, storage and distribution ...
...,s designed to provide accurate information on com...2 (HealthDay News) -- Two leading U.S. psychiatric...ed to help parents deal with the torrent of often ...ications, the ADHD Parents Medication Guide , co-...
...cognition Highlights Kaiser Permanente,s Commitmen...S.,Environmental Protection Agency and the Green E...nte as a "Green Electronics Champion" for its,lead...en" when buying electronic products. The EPA, in ...
...atement of Matthew L. Myers, President, Campaign f...lowing is a,Statement of Matthew L. Myers, Preside... for Tobacco-Free Kids applauds Tyra Banks and her...about it. Last week,s season premiere of "America,...
Other Medicine News:Health News:Medical Affairs: Building Efficient Medical Affairs Functions That Drive Product Marketing Success 2Health News:Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting 2Health News:Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting 3Health News:Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting 4Health News:Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting 5Health News:Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting 6Health News:Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting 7Health News:Doctors' Groups Offer ADHD Guide for Parents 2Health News:Doctors' Groups Offer ADHD Guide for Parents 3Health News:Kaiser Permanente Named Green Electronics Champion by EPA, Green Electronics Council 2Health News:Kaiser Permanente Named Green Electronics Champion by EPA, Green Electronics Council 3Health News:Tobacco-Free Kids Applauds Tyra Banks for Exposing the Ugly Truth About Smoking 2
...logy, the wire crosses the lesion first, independe...actions, including filter placement and retrieval,...ur over the wire., ,Emboshield is designed to ... stenting procedure, and it is the only filter to ...
...oratory has been uniquely designed to fit the need...ning multi-facilities. From test initiation and pr...ivable, Centricity Ultra facilitates quick, effici...modules are fully integrated and reside under a si...
MICROWELL ELISA HUMAN GROWTH HORMONE (hGH) ENZYME IMMUNOASSAY TEST KIT
...ne sulfate (DHEA-S) is the sulfate ester of DHEA, ...conversion of DHEA in adrenal and extradrenal tiss... adrenal cortex, and is a precursor for testostero...ively weak androgenic activity, which for unsulfat...
Medicine Products: